Epetraborole + Epetraborole + Placebo + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mycobacterium Abscessus Infection
Conditions
Mycobacterium Abscessus Infection
Trial Timeline
Mar 1, 2026 → Dec 1, 2027
NCT ID
NCT07301320About Epetraborole + Epetraborole + Placebo + Placebo
Epetraborole + Epetraborole + Placebo + Placebo is a phase 2 stage product being developed by AN2 Therapeutics for Mycobacterium Abscessus Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07301320. Target conditions include Mycobacterium Abscessus Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07301320 | Phase 2 | Recruiting |
Competing Products
20 competing products in Mycobacterium Abscessus Infection